Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Codiak BioSciences, Inc.    CDAK

CODIAK BIOSCIENCES, INC.

(CDAK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/05/2021 04/06/2021 04/07/2021 04/08/2021 04/09/2021 Date
13.61(c) 13.4(c) 14.03(c) 14.53(c) 15.49(c) Last
165 373 111 233 91 927 61 856 96 243 Volume
-6.46% -1.54% +4.70% +3.56% +6.61% Change
More quotes
Financials (USD)
Sales 2021 3,79 M - -
Net income 2021 -78,0 M - -
Net Debt 2021 13,3 M - -
P/E ratio 2021 -3,87x
Yield 2021 -
Sales 2022 7,12 M - -
Net income 2022 -86,7 M - -
Net cash position 2022 74,9 M - -
P/E ratio 2022 -5,28x
Yield 2022 -
Capitalization 341 M 341 M -
EV / Sales 2021 93,5x
EV / Sales 2022 37,3x
Nbr of Employees 105
Free-Float 87,3%
More Financials
Company
Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of exosome-based therapeutics. The Company has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. It utilizes the engEx Platform to generate a pipeline of engineered exosomes... 
More about the company
Notations Surperformance© of Codiak BioSciences, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about CODIAK BIOSCIENCES, INC.
04/10Codiak Presents Data at AACR 2021 Demonstrating Potential of Engineered Exoso..
GL
04/08CODIAK BIOSCIENCES, INC.  : Regulation FD Disclosure (form 8-K)
AQ
03/26CODIAK BIOSCIENCES, INC.  : Change in Directors or Principal Officers (form 8-K)
AQ
03/18CODIAK BIOSCIENCES  : Wedbush Adjusts Codiak BioSciences' Price Target to $34 Fr..
MT
03/17CODIAK BIOSCIENCES  : Management's Discussion and Analysis of Financial Conditio..
AQ
03/17CODIAK BIOSCIENCES  : Reports Q4 Net Loss, Higher Revenue
MT
03/17CODIAK BIOSCIENCES, INC.  : Results of Operations and Financial Condition, Finan..
AQ
03/17CODIAK BIOSCIENCES  : Earnings Flash (CDAK) CODIAK BIOSCIENCES Reports Q4 Loss $..
MT
03/17CODIAK BIOSCIENCES  : Earnings Flash (CDAK) CODIAK BIOSCIENCES Posts Q4 Revenue ..
MT
03/17CODIAK BIOSCIENCES  : Reports Fourth Quarter and Full Year 2020 Financial Result..
AQ
03/10Codiak to Present Data from Two Novel Engineered Exosome Therapeutic Candidat..
GL
03/08CODIAK BIOSCIENCES, INC.  : Change in Directors or Principal Officers (form 8-K)
AQ
02/17CODIAK BIOSCIENCES  : Announces Closing of $66.4 Million Public Offering, Includ..
AQ
02/12CODIAK BIOSCIENCES  : Prices Common Stock Offering at $21 Per Share
MT
02/11Codiak Announces Pricing of $57.8 Million Public Offering of Common Stock
GL
More news
News in other languages on CODIAK BIOSCIENCES, INC.

- No features available -

More news
Analyst Recommendations on CODIAK BIOSCIENCES, INC.
More recommendations
Chart CODIAK BIOSCIENCES, INC.
Duration : Period :
Codiak BioSciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CODIAK BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 36,67 $
Last Close Price 15,49 $
Spread / Highest target 191%
Spread / Average Target 137%
Spread / Lowest Target 100%
EPS Revisions
Managers and Directors
NameTitle
Douglas E. Williams President, Chief Executive Officer & Director
Linda C. Bain Chief Financial Officer
Steven H. Gillis Chairman
Benny Sorensen Senior Vice President & Head-Clinical Development
Yalonda Howze Secretary, EVP, Chief Legal & Compliance Officer
Sector and Competitors
1st jan.Capitalization (M$)
CODIAK BIOSCIENCES, INC.-52.04%341
MODERNA, INC.34.89%56 442
LONZA GROUP AG-3.59%43 993
IQVIA HOLDINGS INC.15.90%39 822
CELLTRION, INC.-13.79%37 705
SEAGEN INC.-18.44%25 900